These authors also suggested that significant co-occurrence of KMT2C/KMT2D mutations with TP53 (and several other) mutations may indicate their role in epigenetic priming of early tumor cells for acquisition of additional genetic mutations (79). This evidence concerns the gene TP53 and neoplasm.